Traumatic brain injury (TBI) is one of the most prevalent causes of worldwide mortality and morbidity in youth, and its treatment usually costs an enormous amount in medical and social welfare (Kraus and McArthur 1996) . It is estimated that 1.1-1.7% of people living in the United States are suffering from a long-term TBI-associated disability (Murphy and Carmine 2012) . Brain edema appears to be a major cause of severe neuronal death induction after TBI. Our recent studies demonstrated that the ion transporter, Na-K-Cl-co-transporter (NKCC1), plays a critical role in TBIinduced brain edema through the activation of the MAPK cascade (Lu et al. 2008 (Lu et al. , 2015 . Although these results have provided the first delineation of the involvement of NKCC1 in TBI-induced brain edema, the detailed mechanism remains unclear.
The recent discovery of the transient receptor potential (TRP) superfamily of cation channels expedited a further understanding of the mechanisms by which cells are able to sense various stimuli such as osmolarity, mechanical loading, heat, and cold (Chung et al. 2003) . Channels of the TRP superfamily potentially play essential roles in diverse homeostatic functions. The superfamily of TRP can be divided into seven protein families: TRPC, TRPV, TRPM, TRPP, TRPML, TRPA, and TRPN (Everaerts et al. 2010; Guilak et al. 2010) . Among these, one member of the TRP vanilloid (TRPV) family, TRPV4, is widely expressed in various organs such as the liver, kidney (Tian et al. 2004) , and heart (Strotmann et al. 2000) . In the nervous system, TRPV4 is present throughout the brain, including the cortex, hippocampus, hypothalamus, and choroids plexus (Liedtke et al. 2000) . TRPV4 is hyperactivated during ischemia, leading to Ca 2+ influx (Lipski et al. 2006) , and its activation correlates with the regulation of pAkt/Akt, B-Raf, and pERK/ERK (Gradilone et al. 2010) . TRPV4 activation also increases the hippocampal NMDA-activated current (I NMDA ) (Li et al. 2013) , and this effect could be attenuated by the administration of a TRPV4 antagonist. A defect in TRPV4 production not only protects neurons from oxygen-glucose deprivation-induced neuronal injury but also increases the viability of astrocytes to oxidative stress (Bai and Lipski 2010; Li et al. 2013) .
The MAPK pathway is suspected to be in involved in TBIinduced neuronal damage and TBI-induced brain edema (Lu et al. 2005a,b) . We have found that TBI-associated NKCC1 activation not only stimulates MAPK cascade phosphorylation but also increases the intracellular free [Ca 2+ ] (Lu et al. 2008) . As NKCC1 has been known to interact with TRPV4, leading to a marked decrease of cell surface expression and impeding its response to hypotonicity (Fu et al. 2006) , we hypothesized that TRPV4 participated in TBI-induced NKCC1 activation and cytotoxic brain edema via MAPK cascade. To evaluate the potential mechanisms involved, hippocampal NKCC1 and TRPV4 expression, MAPK cascade protein phosphorylation, brain edema level, and neuronal damage after TBI were evaluated, and the effects were compared to those after TBI with administration of either a TRPV4 antagonist or TRPV4 antisense oligonucleotide.
Materials and methods

Experimental groups
Adult male Wistar rats weighing 350-400 g were used in this study. The rats were purchased from BioLASCO, Taiwan, Co., Ltd., YiLan, Taiwan and housed individually in a temperature-controlled animal colony at 24°C, with a normal 12 : 12-h light/dark cycle. Rats were given ad libitum access to food and water and were allowed to acclimate to the light/dark cycle at 25°C for at least 1 week before being used in the experiments. The animals were randomly distributed to every group. As a TBI model, a special weight-drop device with a foam bed on the bottom, similar to that described by Marmarou et al. (1994) , was used to deliver a standard traumatic impact to the animals. Each rat was anesthetized under pentobarbital anesthesia (40 mg/kg, i.p.). A metal helmet was then sewn onto the top of the skull to prevent the possibility of a fracture from the trauma-inducing impact. Rats were then placed in a prone position on the bottom plate of the weight-drop device, and a 450 g weight was allowed to fall freely and vertically from a height of 1.8 m onto the metal helmet. To elucidate the activity of TRPV4 in TBI-induced brain edema, the TRPV4 non-specific TRPV4 inhibitor, ruthenium red (8.6 mg/kg; Sigma, St Louis, MO, USA) (Amann et al., 1990 ) and more specific TRPV4 antagonist (RN1734, 1 mg/kg, i.p.; Sigma-Aldrich, St. Louis, MO, USA) (Fichna et al. 2012) , were administered immediately after TBI. Similar to our earlier study (Lu et al. 2008) , some groups of rats were intravenously injected with bumetanide, an NKCC1-specific inhibitor (15.2 mg/kg, Sigma-Aldrich). The protocols for all animal experiments were approved by the Animal Care and Use Committee of the National Chia-Yi University (No. 101033).
TRPV4 antisense administration
To elucidate the role of TRPV4 and its correlation with the level of NKCC1 in TBI-induced brain edema and neuronal damage, certain groups of rats were administered a TRPV4 gene-specific antisense oligonucleotide. The sequence of the TRPV4 antisense oligonucleotide used in this study was 5 0 -CATCACCAGGATCTGCCA TACTG-3 0 (i.c.v., 10 ll; Operon Biotechnologies GmbH, K€ oln, Germany) and was modified from Weiss et al. (Weiss et al. 1997) .
Western blot analysis
The protein samples from the brain tissue with various treatments were resolved in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The post-TBI rats (n = 4 to 6 in each group) were decapitated, at different time points after TBI, and the brains were removed. Following the dissection, each hippocampus was weighed and promptly homogenized in six volumes (v/w) of ice-cold homogenizing buffer containing 9.91 mM tris-base, 0.32 M sucrose, 1 mM EDTA, and a mix of proteases (phenylmethylsulfonyl fluoride: 100 ll/10 mL; leupeptin: 100 ll/10 mL; aprotinin: 100 ll/10 mL). Total proteins were fractionated on an 8% sodium dodecyl sulfate-polyacrylamide gel, and the resolved proteins were electrophoretically transferred to a polyvinylidene difluoride membrane. The blotted membrane was then subjected to antibody detection. Polyclonal anti-TRPV4 (1 : 3000 dilution; Abcam, Cambridge, USA) (Alexander et al. 2013 ) and monoclonal anti-NKCC1 (1 : 5000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies were separately used as primary antibodies. The bound primary antibodies were then detected by the secondary rabbit anti-goat antibody (1 : 5000 dilution; Invitrogen, Carlsbad, CA, USA) and visualized by an enhanced chemiluminescence assay (RPN 2108; Amersham International, Amersham, UK). We used atubulin as the internal control (1 : 5000 dilution; Santa Cruz Biotechnology). The relative protein levels of TRPV4, NKCC1, MEK, ERK, Akt, phosphorylated MEK, phosphorylated ERK, and phosphorylated Akt were finally quantified using a semi-quantitative densitometry equipped with AlphaEase software (Alpha Innotech Corp, San Leandro, CA USA).
Water content measurement Rats were decapitated under deep anesthesia with 100 mg/kg pentobarbital. The brains were quickly removed, and their wet weights were measured. Each brain was then dried at 120°C for 24 h, and the weight was recorded again. Water content of each rat brain was calculated based on the difference between wet and dry weight and expressed as percentage of wet weight. The data analysis was processed in a double-blinded manner.
Statistical analysis
Values are presented as the mean AE SEM. Physiological variables were compared between sham, TBI, and bumetanide-treated groups during pre-trauma and post-trauma by analysis of variance. Significant changes of phosphorylated Raf, phosphorylated MEK, and phosphorylated ERK were determined by the non-parametric MannWhitney U-test. Water content was compared between sham, TBI, and bumetanide-treated groups by the non-parametric MannWhitney U-test. P < 0.05 was considered statistically significant.
Results
Up-regulation of hippocampal TRPV4 after TBI The first experiment conducted in this study was to examine the possible alteration in TRPV4 expression in the hippocampus after TBI. Compared with the expression level in the sham group, the TRPV4 expression level was found to increase slightly 4 h after TBI induction, and a statistically significant elevation in the protein level was found at 8-12 h after TBI (Fig. 1a and b) . As the profound effect of TBI exerted on the stimulation of TRPV4 occurred 8 h post-TBI, the rest of the experiments adopted this time point. This TBIinduced stimulation of TRPV4 expression was alleviated by the administration of TRPV4 antisense oligonucleotide immediately after TBI. As shown in the western blot analysis ( Fig. 1c and d) , microinjection of TRPV4 antisense oligonucleotide into the lateral ventricle drastically decreased the TBI-induced TRPV4 production by approximately 30%. The specificity of the TRPV4 antisense oligonucleotide was verified, as the similar effect was not observed when a random oligonucleotide was used.
Administration of TRPV4 antagonist protects animals from TBI-induced brain edema As observed in our previous studies, severe brain edema appeared to be another neurological consequence induced by TBI. In this study, we attempted to evaluate the involvement of TRPV4 in the formation of TBI-induced brain edema. In comparison with the sham group, as expected, TBI led to a severe brain edema. This TBI-associated brain edema could be effectively diminished by the administration of ruthenium red (a non-specific antagonist), RN1734 (a specific TRPV4 antagonist), and TRPV4 antisense oligonucleotide (Fig. 2) .
TRPV4 is essential for the TBI-induced MAPK cascade activation Since many neurological responses, including TBI-induced neuron damage and edema, have been demonstrated to be mediated by the activation of MAPK cascades, it is of particular interest to know whether the same cascade is also regulated by TRPV4. We first analyzed the effect of ruthenium red (a non-specific TRPV4 antagonist) on the MAPK cascade phosphorylation (Fig. 3) and then analyzed the effect of RN1734 (a specific TRPV4 antagonist) administration on the kinase phosphorylation of the TBIinduced MAPK cascade (Fig. 4) . Compared with sham groups, TBI actually triggered a significant increase in the phosphorylation of MEK ( Fig. 3a and b) ( Fig. 4a and b) , ERK ( Fig. 3c and d ) ( Fig. 4c and d) , and Akt ( Fig. 3e and f) (Fig. 4e and f) . The activation of these kinases, however, was effectively abrogated by the TRPV4 inhibitor. RN1734 administration (lanes: TBI-8 h+RN1734) repressed the TBIinduced phosphorylation of MEK to 47%, ERK to 41%, and Akt to 47%. These results clearly implied that the activation of the MAPK cascade post-TBI was mediated by TRPV4 and that TRPV4 activated the MAPK cascade after TBI.
TBI-induced TRPV4 expression is regulated by NKCC1
In our earlier studies, TBI-induced brain edema was found to be mediated by the ion transporter, NKCC1. The activation of NKCC1 that occurred after TBI also conferred MAPK cascade stimulation. We validated this again in this study. After TBI, NKCC1 expression was significantly upregulated, and administration of the NKCC1 inhibitor, bumetanide, attenuated the TBI-induced phosphorylation of the kinases in the MAPK cascade, that is, MEK, ERK, and AKT ( Fig. 5a-f) . Bumetanide also effectively decreased the TBI-induced brain edema (Fig. 6) . These results combined suggest that both NKCC1 and TRPV4 were up-regulated post-TBI and eventually led to brain edema, and the activation of the MAPK cascade seemed to be the shared pathway. This led us to explore the correlation between NKCC1 and TRPV4. In this study, we adopted a cross-inhibition strategy to examine the levels of NKCC1 and TRPV4 in the presence of either RN1734 or bumetanide. We found that bumetanide administration reversed the TBI-induced expression of TRPV4 to the level roughly equivalent to that of the sham group ( Fig. 7a  and b) . However, the injection of RN1734 seemed to insignificantly affect the NKCC1 expression after TBI ( Fig. 7c and d) .
Discussion
This study illustrated the role of TRPV4 in TBI-induced brain edema and its possible mechanisms. Following TBI, the expression of TRPV4 is significantly increased. Similar to our previous studies, the up-regulation of TRPV4 was parallel to the up-regulation of NKCC1 and Raf/MEK/ERK phosphorylation, as well as the level of TBI-induced brain edema. We also further investigated the relationship between TRPV4 and NKCC1. In this study, we found the blockade of NKCC1 also attenuated the up-regulation of TRPV4; however, there was no significant effect of TRPV4 blockade on NKCC1 expression. Our finding clearly suggests that TRPV4 participated in the TBI-induced brain edema mediated by NKCC1 activation, and the effects of TRPV4 were mediated by the ERK cascade (Fig. 8) . NKCC1 is essential for ion homeostasis and volume regulation in neurons and astrocytes and is regulated by various neurotransmitters and hormones (O'Donnell et al. 2006) . Our previous study provided evidence that NKCC1 is critical to TBI-induced brain edema through its actions on the MAPK cascade (Lu et al. 2008) . This study suggested that NKCC1 is also necessary for TRPV4 activation, which then further activates the MAPK cascade. The possible mechanism may be because of activation of NKCC1 after TBIinduced severe cytotoxic edema, which consequently induces TRPV4 expression. In addition, NKCC1 stimulation increases intracellular Ca 2+ and is proposed to affect the signal transduction pathway (Dempsey et al. 2000; Payne et al. 2003; Panet et al. 2006) . The effects of intracellular Ca 2+ are controversial; depending on the concentration, either an enhancement or inhibition of TRPV4 channel activity may occur (Watanabe et al. 2003; Everaerts et al. 2010; Strotmann et al. 2010) . It has been shown that elevated Ca 2+ levels may be responsible for spontaneous activation of TRPV4 channels in non-stimulated TRPV4-expressing cells (Watanabe et al. 2003) . TRPV4 activation also induces the influx of Ca 2+ , which exacerbates the circuit that induces severe brain edema.
A large number of studies have indicated that inflammation is important to TBI-induced secondary damage to neurons, glia, and myelin (Kunz et al. 2002; Cernak et al. 2004) . Administration of indomethacin protects animals from TBI-induced neuroinflammation (Chao et al. 2012 ). In our previous study, we found that TBI induced various inflammatory responses, including interleukin-1 release, the accumulation of leukocytes, and activation of macrophages and microglia (Lu et al. 2005a,b) . TRPV4 is not only expressed in the pyramidal neurons of the hippocampus but also astrocytes in the cortex and hippocampus (Benfenati et al. 2007; Shibasaki et al. 2007) . There is also evidence that TRPV4 immunoreactivity significantly increases in hippocampal astrocytes starting 1 h after ischemia and reaches maximal level 7 days after ischemia (Benfenati et al. 2011; Butenko et al. 2012) . Ischemia has also been shown to enhance TRPV4 expression along with GFAP expression, astrocyte hypertrophy, and astrocytic proliferation (Anderova et al. 2011) , which suggests that TRPV4 plays an important role in inflammation-induced astrocyte activation. Vriens et al. (2004) indicated that the endocannabinoid anandamide and its hydrolysis product arachidonic acid (AA) are potent endogenous agonists for TRPV4. PGE 2 , a COX-derived metabolite of AA, is significantly elevated in the plasma of traumatized patients and animals (Mackrell et al. 2001; Yan et al. 2004) and is important for macrophage activation, which secretes toxic cytokines and cause further neuronal damage. TRPV4 has been shown to be up-regulated by PGE 2 sensitization (Alessandri-Haber et al. 2003 , and interleukin-1 has been suggested to up-regulate PGE 2 and TRPV4 expression (Ma et al. 2008) , which enhances TBI-induced hippocampal TRPV4 over-expression.
After TBI, brain edema progresses from the hemorrhagic core with necrotic tissue and incorporates uninjured tissue adjacent to the lesion (Bullock et al. 1990; Bareyre et al. 1997; Unterberg et al. 1997) . Cytotoxic edema and vasogenic edema are the major causes of TBI-induced severe neuronal death, evidenced by TBI patients (Bullock et al. 1990) and various TBI models such as the fluid percussion model (Bareyre et al. 1997) , control cortical impact (Unterberg et al. 1997; Stroop et al. 1998) , and weight-drop model (Lu et al. 2007 ). Cytotoxic edema is caused by energy failure leading to intracellular fluid accumulation. The results obtained from this study are consistent with our previous studies which suggested that the expression of NKCC1 is significantly elevated after TBI and blockade of NKCC1 attenuates the brain edema formation (Lu et al. 2007 ). On the other hand, vasogenic edema develops because of the disruption of the blood-brain barrier (BBB), which induces the subsequent increase in intracranial pressure, furthering neuronal damage. The BBB is composed of astrocytes and endothelial cells. Activation of TRPV4 increases the [Ca 2+ ]i and activates the large conductance Ca-activated K (BK) channel, providing the transcellular ion pathway and increasing the paracellular pathway (Grunnet et al. 2005; Reiter et al. 2006) . These studies implied that with TRPV4 activation after TBI, a change in tight junction structure caused the BBB epithelial cells to lose their sealing properties and become more permeable to small molecules, which induces severe vasogenic brain edema.
In conclusion, our results suggest that the activation of NKCC1 and TRPV4 after TBI appear in a positive feedback Fig. 8 The proposed pathway for the role of Na-K-Cl-co-transporter (NKCC1) and transient receptor potential vanilloid type 4 (TRPV4) in traumatic brain injury (TBI)-induced brain edema. The stimulation of NKCC1 after TBI triggers a sequential response including the activation of TRPV4, the MAPK pathway, and Akt. Activated NKCC1 then promotes the up-regulation of TRPV4 that facilitates brain edema.
pattern and further exacerbate TBI-induced brain edema and neuron death.
